Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22.


A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8-30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53-222), with 5-year OS rate of 77% (95% CI: 61.0-87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.

Keywords: Early-onset multiple myeloma; prognosis; survival; treatment response.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Combined Modality Therapy
  • Cytogenetic Analysis
  • Disease Management
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / epidemiology*
  • Multiple Myeloma / etiology
  • Multiple Myeloma / therapy
  • Outcome Assessment, Health Care
  • Patient Selection
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult